Details
Stereochemistry | UNKNOWN |
Molecular Formula | C12H18ClN |
Molecular Weight | 211.731 |
Optical Activity | ( - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CC1=CC=CC=C1)NCCCCl
InChI
InChIKey=XXVROGAVTTXONC-UHFFFAOYSA-N
InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3743406Curator's Comment: description was created based on several sources, including, http://ec.europa.eu/health/documents/community-register/2000/200003093430/anx_3430_en.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3743406
Curator's Comment: description was created based on several sources, including, http://ec.europa.eu/health/documents/community-register/2000/200003093430/anx_3430_en.pdf
Mefenorex or (+/-)N-(3-chloropropyl)-1-methyl-2-phenylethylamine is an N-alkylated analogue of amphetamine. The therapeutic efficacy of mefenorex as an adjunctive support in the treatment of obesity for limited periods of time, as well as its ability to be well tolerated, has been amply demonstrated. Mefenorex is considered to be racemic mixture, no available data regarding enantiospecific pharmacological activity of the compound.
CNS Activity
Originator
Sources: http://www.google.ru/patents/DE1210873B
Curator's Comment: # Hoffmann-La Roche
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/37853
40 mg/day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7FT4O2NC8G
Created by
admin on Sat Dec 16 10:30:28 GMT 2023 , Edited by admin on Sat Dec 16 10:30:28 GMT 2023
|
PRIMARY | |||
|
111051-42-4
Created by
admin on Sat Dec 16 10:30:28 GMT 2023 , Edited by admin on Sat Dec 16 10:30:28 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD